Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
AssigneeAllergan, Inc.
InventorsJanet A. Takeuchi, Ling Li, Wha Bin Im
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
Claims8
A method of treating an autoimmune disease associated with the sphingosine-1-phosphate receptor modulation, wherein the autoimmune disease is psoriasis in a mammal in need thereof, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by Formula I or a pharmaceutically acceptable salt thereof:
- wherein:
- represents a single
- or a double bond
- A is hydrogen;
- R2 is hydrogen;
- R3 is hydrogen;
- R4 is PO3H2;
- R5 is hydrogen;
- R6 is hydrogen;
- R7 is hydrogen;
- L1 is CHR12;
- L2 is CHR13;
- R12 is hydrogen;
- R13 is hydrogen;
- a is 0;
- b is 1;
- c is 0, 1, 2, 3 or 4;
- d is 1, 2, 3 or 4;
- and
- R1 is O or CH2.
A method of treating an autoimmune disease associated with the sphingosine-1-phosphate receptor modulation, wherein the autoimmune disease is psoriasis, in a mammal in need thereof, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by Formula II or a pharmaceutically acceptable salt thereof:
- wherein:
- represents a double bond
- A is hydrogen;
- R2 is hydrogen;
- R3 is hydrogen;
- R4 is PO3H2;
- R5 is hydrogen;
- R6 is hydrogen;
- R7 is hydrogen;
- L1 is CHR12;
- L2 is CHR13;
- R12 is hydrogen;
- R13 is hydrogen;
- a1 is 0;
- b is 1;
- c is 0, 1, 2, 3 or 4;
- and
- d is 1, 2, 3 or 4;
- provided that when a1 is 0 then R1a is O.
Dependencies are inferred from the claim text.